Important information about the IVD products from DCS Diagnostik-Systeme

Due to the requirements of the In Vitro Diagnostic Medical Devices Regulation (IVDR), DCS Diagnostik-Systeme will no longer be able to manufacture its IVD antibodies in the future. The reason for this is the IVDR’s regulatory transition periods for Class C products. Since the transition period for these products ends on May 26, 2026, they may no longer be manufactured after that date without the appropriate IVDR certification. Only stock that has already been produced may still be sold after that date.

We deeply regret this development, but we would like to assure you that BIOZOL remains a reliable partner. Our portfolio already includes several alternative manufacturers that also offer high-quality IVD antibodies and other reagents for immunohistochemistry. Among others these include GenomeMe, Bio SB, DB Biotech und BioGenex,

We would be happy to work with you to identify alternative products suitable for your applications, and we are happy to provide you with test samples. Of course, we will assist you in selecting the right products and with any technical or logistical questions regarding the transition. Please don’t hesitate to contact us—we will provide personalized advice and ensure the transition goes as smoothly as possible.

 

 

DCS Innovative Diagnostic Systems History

DCS Innovative Diagnostics Systems was founded in 1992 and has been ISO 13485-certified since 2000. The portfolio focuses on biochemical and immunological reagents and detection systems, including semi-automated systems, reagents, chromogens, and antibodies. In 2025, DCS was acquired by Calibre Scientific and continues as a proprietary brand of BIOZOL. With the changes to the In Vitro Diagnostic Medical Devices Regulation (IVDR), a large portion of the antibodies are no longer available.

 

---

This landing page replaces the previous website on www.dcs-diagnostics.de

---